Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15
Taysha Gene Therapies (NASDAQ: TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS disorders, has scheduled its Q1 2025 financial results release and corporate update for May 15, 2025, at 8:30 AM ET. The company will host a conference call and webcast accessible via toll-free and international dial-in numbers, with a dedicated conference ID. Investors and interested parties can also access the webcast through Taysha's investor relations website.
Taysha Gene Therapies (NASDAQ: TSHA), una società biotecnologica in fase clinica specializzata in terapie geniche basate su AAV per disturbi del sistema nervoso centrale, ha programmato la pubblicazione dei risultati finanziari del primo trimestre 2025 e un aggiornamento aziendale per il 15 maggio 2025, alle 8:30 ET. La società terrà una conference call e una webcast accessibili tramite numeri verdi e numeri internazionali con un ID conferenza dedicato. Investitori e parti interessate potranno inoltre seguire la webcast tramite il sito web delle relazioni con gli investitori di Taysha.
Taysha Gene Therapies (NASDAQ: TSHA), una compañía biotecnológica en etapa clínica especializada en terapias génicas basadas en AAV para trastornos del sistema nervioso central, ha programado la publicación de sus resultados financieros del primer trimestre de 2025 y una actualización corporativa para el 15 de mayo de 2025 a las 8:30 AM ET. La compañía llevará a cabo una llamada de conferencia y una transmisión en vivo accesibles mediante números gratuitos y números internacionales, con un ID de conferencia dedicado. Los inversores y partes interesadas también podrán acceder a la transmisión a través del sitio web de relaciones con inversionistas de Taysha.
Taysha Gene Therapies (NASDAQ: TSHA)는 중추신경계 질환을 위한 AAV 기반 유전자 치료제를 전문으로 하는 임상 단계 바이오테크 기업으로, 2025년 1분기 재무실적 발표 및 기업 업데이트를 2025년 5월 15일 오전 8시 30분(동부시간)에 예정하고 있습니다. 회사는 전용 회의 ID와 함께 무료 전화 및 국제 전화 번호를 통해 접속 가능한 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 투자자 및 관심 있는 분들은 Taysha 투자자 관계 웹사이트를 통해서도 웹캐스트에 접속할 수 있습니다.
Taysha Gene Therapies (NASDAQ : TSHA), une société biotechnologique en phase clinique spécialisée dans les thérapies géniques à base de AAV pour les troubles du système nerveux central, a programmé la publication de ses résultats financiers du premier trimestre 2025 et une mise à jour d'entreprise pour le 15 mai 2025 à 8h30 ET. La société organisera une conférence téléphonique et une webdiffusion accessibles via des numéros gratuits et internationaux, avec un identifiant de conférence dédié. Les investisseurs et parties intéressées pourront également accéder à la webdiffusion via le site web des relations investisseurs de Taysha.
Taysha Gene Therapies (NASDAQ: TSHA), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf AAV-basierte Gentherapien für Erkrankungen des zentralen Nervensystems spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 und ein Unternehmensupdate für den 15. Mai 2025 um 8:30 Uhr ET angekündigt. Das Unternehmen wird eine Telefonkonferenz und einen Webcast veranstalten, die über gebührenfreie und internationale Einwahlnummern mit einer eigenen Konferenz-ID zugänglich sind. Investoren und Interessierte können den Webcast auch über die Investor-Relations-Website von Taysha verfolgen.
- None.
- None.
DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the first quarter ended March 31, 2025, and host a corporate update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM Eastern Time.
Conference Call Details
Thursday, May 15, at 8:30 AM Eastern Time / 7:30 AM Central Time
Toll Free: 877-407-0792
International: 201-689-8263
Conference ID: 13753490
Webcast: https://ir.tayshagtx.com/news-events/events-presentations
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.
Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com
Media Contact:
Carolyn Hawley
Inizio Evoke
carolyn.hawley@inizioevoke.com
FAQ
When will Taysha Gene Therapies (TSHA) release its Q1 2025 earnings?
How can investors join Taysha Gene Therapies' Q1 2025 earnings call?
What is Taysha Gene Therapies' main business focus?
What stock exchange is Taysha Gene Therapies listed on?
